FibroGen to Present at Bank of America Securities 2020 Health Care Conference

Rhea-AI Summary

FibroGen (NASDAQ: FGEN) will participate in the virtual Bank of America Securities 2020 Health Care Conference from May 12-14, 2020. CEO Enrique Conterno is set for a fireside chat on May 14 at 11:00 AM ET, which will be available via live audio webcast on the FibroGen website. The chat will also have a 30-day replay option.

FibroGen focuses on developing innovative therapeutics, including roxadustat for anemia related to chronic kidney disease and other conditions, and pamrevlumab for multiple serious illnesses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be available for 30 days.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy (DMD). For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Media Inquiries:
Sara Iacovino
1.703.474.4452
sara.iacovino@gcihealth.com

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

FAQ

When will FibroGen participate in the Bank of America Securities Health Care Conference?

FibroGen will participate in the conference from May 12-14, 2020.

What time is the FibroGen CEO's fireside chat during the conference?

The fireside chat featuring CEO Enrique Conterno is scheduled for May 14 at 11:00 AM ET.

How can I access the FibroGen CEO's fireside chat?

The chat can be accessed via a live audio webcast on the FibroGen website.

What is roxadustat developed by FibroGen used for?

Roxadustat is developed for treating anemia associated with chronic kidney disease and other conditions.

What other therapeutic candidate is FibroGen developing?

FibroGen is also developing pamrevlumab, an anti-CTGF human monoclonal antibody, for various severe diseases.